Raleigh Capital Management Inc. Purchases 1,100 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Raleigh Capital Management Inc. raised its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 1,100.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,200 shares of the company’s stock after purchasing an additional 1,100 shares during the quarter. Raleigh Capital Management Inc.’s holdings in Hims & Hers Health were worth $29,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in HIMS. Amalgamated Bank lifted its holdings in Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after purchasing an additional 2,354 shares during the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in Hims & Hers Health during the 2nd quarter valued at $303,000. Xponance Inc. acquired a new stake in shares of Hims & Hers Health during the second quarter worth $242,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Hims & Hers Health by 44.9% during the second quarter. The Manufacturers Life Insurance Company now owns 116,477 shares of the company’s stock worth $2,352,000 after buying an additional 36,081 shares in the last quarter. Finally, Scientech Research LLC acquired a new stake in shares of Hims & Hers Health during the second quarter worth $1,474,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analysts Set New Price Targets

HIMS has been the subject of a number of research reports. TD Cowen reissued a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Morgan Stanley initiated coverage on Hims & Hers Health in a report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price for the company. BTIG Research initiated coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price for the company. Finally, Piper Sandler lifted their target price on Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a report on Monday, January 6th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $25.13.

Hims & Hers Health Stock Down 0.0 %

Hims & Hers Health stock opened at $30.89 on Friday. Hims & Hers Health, Inc. has a 12-month low of $8.51 and a 12-month high of $35.02. The business’s 50-day moving average price is $28.22 and its two-hundred day moving average price is $22.17. The stock has a market cap of $6.75 billion, a PE ratio of 70.20 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter in the previous year, the business posted ($0.04) earnings per share. The business’s revenue for the quarter was up 77.1% on a year-over-year basis. As a group, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $33.56, for a total transaction of $68,932.24. Following the sale, the insider now directly owns 184,947 shares in the company, valued at approximately $6,206,821.32. The trade was a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 27,098 shares of the business’s stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $30.08, for a total value of $815,107.84. Following the sale, the chief executive officer now owns 27,918 shares in the company, valued at approximately $839,773.44. This trade represents a 49.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,258,406 shares of company stock worth $34,513,657 over the last 90 days. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.